BMAL2 promotes eCIRP-induced macrophage endotoxin tolerance

被引:0
|
作者
Zhou, Mian [1 ]
Aziz, Monowar [1 ,2 ,3 ]
Li, Jingsong [1 ]
Jha, Alok [1 ]
Ma, Gaifeng [1 ]
Murao, Atsushi [1 ]
Wang, Ping [1 ,2 ,3 ]
机构
[1] Feinstein Inst Med Res, Ctr Immunol & Inflammat, Manhasset, NY 11030 USA
[2] Zucker Sch Med Hofstra Northwell, Dept Surg, Manhasset, NY 11549 USA
[3] Zucker Sch Med Hofstra Northwell, Dept Mol Med, Manhasset, NY 11549 USA
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
基金
美国国家卫生研究院;
关键词
eCIRP; macrophages; circadian; BMAL2; PD-L1; immune tolerance; PD-1; EXPRESSION; PROTEIN; INHIBITION;
D O I
10.3389/fimmu.2024.1426682
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background The disruption of the circadian clock is associated with inflammatory and immunological disorders. BMAL2, a critical circadian protein, forms a dimer with CLOCK, activating transcription. Extracellular cold-inducible RNA-binding protein (eCIRP), released during sepsis, can induce macrophage endotoxin tolerance. We hypothesized that eCIRP induces BMAL2 expression and promotes macrophage endotoxin tolerance through triggering receptor expressed on myeloid cells-1 (TREM-1).Methods C57BL/6 wild-type (WT) male mice were subjected to sepsis by cecal ligation and puncture (CLP). Serum levels of eCIRP 20 h post-CLP were assessed by ELISA. Peritoneal macrophages (PerM) were treated with recombinant mouse (rm) CIRP (eCIRP) at various doses for 24 h. The cells were then stimulated with LPS for 5 h. The levels of TNF-alpha and IL-6 in the culture supernatants were assessed by ELISA. PerM were treated with eCIRP for 24 h, and the expression of PD-L1, IL-10, STAT3, TREM-1 and circadian genes such as BMAL2, CRY1, and PER2 was assessed by qPCR. Effect of TREM-1 on eCIRP-induced PerM endotoxin tolerance and PD-L1, IL-10, and STAT3 expression was determined by qPCR using PerM from TREM-1-/- mice. Circadian gene expression profiles in eCIRP-treated macrophages were determined by PCR array and confirmed by qPCR. Induction of BMAL2 activation in bone marrow-derived macrophages was performed by transfection of BMAL2 CRISPR activation plasmid. The interaction of BMAL2 in the PD-L1 promoter was determined by computational modeling and confirmed by the BIAcore assay.Results Serum levels of eCIRP were increased in septic mice compared to sham mice. Macrophages pre-treated with eCIRP exhibited reduced TNF alpha and IL-6 release upon LPS challenge, indicating macrophage endotoxin tolerance. Additionally, eCIRP increased the expression of PD-L1, IL-10, and STAT3, markers of immune tolerance. Interestingly, TREM-1 deficiency reversed eCIRP-induced macrophage endotoxin tolerance and significantly decreased PD-L1, IL-10, and STAT3 expression. PCR array screening of circadian clock genes in peritoneal macrophages treated with eCIRP revealed the elevated expression of BMAL2, CRY1, and PER2. In eCIRP-treated macrophages, TREM-1 deficiency prevented the upregulation of these circadian genes. In macrophages, inducible BMAL2 expression correlated with increased PD-L1 expression. In septic human patients, blood monocytes exhibited increased expression of BMAL2 and PD-L1 in comparison to healthy subjects. Computational modeling and BIAcore assay identified a putative binding region of BMAL2 in the PD-L1 promoter, suggesting BMAL2 positively regulates PD-L1 expression in macrophages.Conclusion eCIRP upregulates BMAL2 expression via TREM-1, leading to macrophage endotoxin tolerance in sepsis. Targeting eCIRP to maintain circadian rhythm may correct endotoxin tolerance and enhance host resistance to bacterial infection.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Rac2 Promotes Alternative Macrophage Activation In Bleomycin Induced Pulmonary Fibrosis
    Joshi, S.
    Singh, A.
    Wong, S.
    Zulcic, M.
    Craig, V.
    Hagood, J.
    Durden, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [22] FcγRI is required for TGFβ2-treated macrophage-induced tolerance
    Gu, Z.
    Chhabra, A. Y.
    Alard, P.
    Warner, D. R.
    Kosiewicz, M. M.
    IMMUNOBIOLOGY, 2013, 218 (09) : 1200 - 1206
  • [23] Pellino-3 promotes endotoxin tolerance and acts as a negative regulator of TLR2 and TLR4 signaling
    Murphy, Michael B.
    Xiong, Yanbao
    Pattabiraman, Goutham
    Manavalan, Tissa T.
    Qiu, Fu
    Medvedev, Andrei E.
    JOURNAL OF LEUKOCYTE BIOLOGY, 2015, 98 (06) : 963 - 974
  • [24] Macrophage Ferroptosis Promotes MMP2/9 Overexpression Induced by Hemin in Hemorrhagic Plaque
    Li, Bicheng
    Lu, Minqiao
    Wang, Hui
    Sheng, Siqi
    Guo, Shuyuan
    Li, Jia
    Tian, Ye
    THROMBOSIS AND HAEMOSTASIS, 2024, 124 (06) : 568 - 580
  • [25] Impairment of endotoxin-induced macrophage inflammatory protein 2 gene expression in alveolar macrophages in Streptozotocin-induced diabetes in mice
    Amano, H
    Yamamoto, H
    Senba, M
    Oishi, K
    Suzuki, S
    Fukushima, K
    Mukaida, N
    Matsushima, K
    Eguchi, K
    Nagatake, T
    INFECTION AND IMMUNITY, 2000, 68 (05) : 2925 - 2929
  • [26] Role of endogenous macrophage inflammatory protein-2 in regulating fever induced by bacterial endotoxin in normal and immunosuppressed rats
    Miñano, FJ
    Tavares, E
    Maldonado, R
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2004, 31 (10) : 723 - 731
  • [27] Compartmentalization of macrophage inflammatory protein-2, but not cytokine-induced neutrophil chemoattractant, in rats challenged with intratracheal endotoxin
    Zhang, P
    Nelson, S
    Holmes, MC
    Summer, WR
    Bagby, GJ
    SHOCK, 2002, 17 (02): : 104 - 108
  • [28] A role for p21 (WAF1/CIP1) in endotoxin tolerance and alternative M2 macrophage polarization
    Rackov, G.
    Balomenos, D.
    IMMUNOLOGY, 2013, 140 : 194 - 194
  • [29] NADPH-OXIDASE 2 ACTIVATION PROMOTES OPIOID-INDUCED ANTINOCICEPTIVE TOLERANCE IN MICE
    Doyle, T.
    Esposito, E.
    Bryant, L.
    Cuzzocrea, S.
    Salvemini, D.
    NEUROSCIENCE, 2013, 241 : 1 - 9
  • [30] M2-macrophage-induced chronic inflammation promotes mesenchymal stromal cell senescence.
    Dyachkova, U. D.
    Vigovskii, M. A.
    Basalova, N. A.
    Aleksandrushkina, N. A.
    Grigorieva, O. A.
    Efimenko, A. Y.
    HUMAN GENE THERAPY, 2021, 32 (19-20) : A144 - A145